TGF-beta RII Binding Proteins for Therapeutic Use

ChangeBridge: EPO Bulletin - Therapeutics (A61P)

Published March 25th, 2026

Detected April 2nd, 2026

Summary

The European Patent Office published patent application EP4081306A1 by Merus B.V. for TGF-beta-RII binding proteins for therapeutic use. The application covers cancer treatment applications (A61P 35/00) and is classified under C07K 16/28 and C07K 16/10. The patent designates all EPC contracting states and was published March 25, 2026.

View original document View source feed page

What changed

The EPO has published patent application EP4081306A1 filed by Merus B.V. claiming TGF-beta-RII binding proteins for therapeutic applications. The application specifically covers cancer treatment (A61P 35/00) and falls under C07K 16/28 (immunoglobulin superfamily) and C07K 16/10 (antiviral antigens) classifications. Inventors include Throsby, Klooster, and de Kruif.

Pharmaceutical companies and biotechnology firms developing TGF-beta targeted therapies should review the patent claims to assess potential licensing requirements or competitive implications. This publication establishes Merus's intellectual property position in the designated EPC states (all EU member states plus other designated countries).

Source document (simplified)

← EPO Patent Bulletin

TGF-BETA-RII BINDING PROTEINS

Publication EP4081306A1 Kind: A1 Mar 25, 2026

Applicants

Merus B.V.

Inventors

THROSBY, Mark, KLOOSTER, Rinse, DE KRUIF, Cornelis Adriaan

IPC Classifications

A61P 35/00 20060101AFI20210707BHEP C07K 16/28 20060101ALI20210707BHEP C07K 16/10 20060101ALI20210707BHEP

Designated States

AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LI, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR

View original document →